Loading clinical trials...
Loading clinical trials...
Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Conditions
Interventions
UCART123
Locations
1
United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
June 28, 2017
Primary Completion Date
June 27, 2019
Completion Date
June 27, 2019
Last Updated
July 31, 2019
NCT06006403
NCT04013685
NCT07007052
Lead Sponsor
Cellectis S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions